Gastroenterologia Japonica

, Volume 27, Issue 1, pp 78–82 | Cite as

Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice

  • Akihiro Funakoshi
  • Akira Kono
Liver, Pancreas, and Biliary Tract


The Human pancreatic carcinoma cell line KP-1N and its clone KP-1NL which has a high rate of liver metastasis were established. Ki-ras DNA point mutation on the codon 12 was found. The growth of KP-1N was stimulated by a physiological range of concentration (10-11–10-10 M) of cholecystokinin and the increase was inhibited by the addition of a cholecystokinin receptor antagonist (CR 1505). Daily injections of CR 1505 (35 mg/kg) diminished the number of tumor colonics in the liver that were formed after an intrasplenic injection of the highly liver metastatic KP-1NL cells. These results suggest that cholecystokinin antagonists may be useful as growth inhibitors for some pancreatic cancer.

Key words

CCK CR 1505 pancreatic cancer cell line 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ohyanagi H, Okumura S, Yamamoto Y, et al: Epidemiological study on pancreatic cancer. Jpn J Cancer Chemother 1985;12: 189–199. (in Japanese)Google Scholar
  2. 2.
    Ikeda Y, Ezaki M, Hayashi I, et al: Establishment and Characterization of Human Pancreatic Cancer Cell Lines in Tissue Culture and in Nude Mice. Jpn J Cancer Res 1990;81:987–993.PubMedGoogle Scholar
  3. 3.
    Townsend CM, Singh P, Thompson JC: Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 1986;91:1002–1006.PubMedGoogle Scholar
  4. 4.
    Frazier ML, Pathak S, Wang Z-W, et al: Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3. Pancreas 1990;5:8–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith JP, Mohesky C, Barrett B, et al: CCK stimulates growth of human pancreatic cancer [Abstract]. Dig Dis Sci 1986;31: 1150.Google Scholar
  6. 6.
    Douglas BR, Wouterson RA, Jansen JBMJ, et al: Influence of cholecystokinin receptor antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 1989;96:462–469.PubMedGoogle Scholar
  7. 7.
    Setnikar I, Bani M, Cereda R, et al: Anticholecystokinin activities of loxiglumide. Arzneim Rorsch 1987;37:1168–1171.Google Scholar
  8. 8.
    Grunewald K, Lyons J, Frohlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037–1041.PubMedCrossRefGoogle Scholar
  9. 9.
    Niederau M, Niederay C, Strohmeyer G, et al: Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo. Am J Physiol 1989;256:G150–157.PubMedGoogle Scholar
  10. 10.
    Smith JP, Kramer ST, Solomon TE: CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept 1991;32:341–349.PubMedCrossRefGoogle Scholar
  11. 11.
    Tada M, Omata M, Ohto M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991;100:233–238.PubMedGoogle Scholar
  12. 12.
    Holland E, Trocheris De St.-Front V, Lowet-Hermitte P, et al: Differentiation features of human pancreatic tumor cells maintained in nude mice and in culture: immunocytochemical and ultrastructural studies. Int J Cancer 1984;34:177–185.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1992

Authors and Affiliations

  • Akihiro Funakoshi
    • 1
  • Akira Kono
    • 2
  1. 1.Division of GastroenterologyNational Kyushu Cancer CenterFukuokaJapan
  2. 2.Chemotherapy Division of Research InstituteNational Kyushu Cancer CenterFukuokaJapan

Personalised recommendations